Navigation Links
ViroPharma To Acquire Lev Pharmaceuticals
Date:7/15/2008

investors and security holders to read the proxy statement/prospectus regarding the proposed merger when it becomes available because it will contain important information.

You may obtain copies of all documents filed with the SEC regarding this transaction, free of charge, at the SEC's website ( http://www.sec.gov ). You may also obtain these documents, free of charge, from ViroPharma's website ( http://www.viropharma.com ) under the tab "Investors" and then under the item "SEC Filings". You may also obtain these documents, free of charge, from Lev's website ( http://www.levpharma.com ) under the tab "Investor Relations" and then under the heading "SEC Filings."

Proxy Solicitation

ViroPharma, Lev and their respective directors, executive officers and certain other members of management and employees may be soliciting proxies from Lev stockholders in favor of the merger. Information regarding the persons who may, under the rules of the SEC, be considered participants in the solicitation of the Lev stockholders in connection with the proposed merger will be set forth in the proxy statement/prospectus when it is filed with the SEC. You can find information about ViroPharma's executive officers and directors in its definitive proxy statement filed with the SEC on April 11, 2008. You can find information about Lev's executive officers and directors in definitive proxy statement filed with the SEC on April 16, 2008. You can obtain free copies of these documents from ViroPharma and Lev using the contact information above.


'/>"/>
SOURCE ViroPharma Incorporated
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9

Related biology technology :

1. ViroPharma to Present at Two Upcoming Healthcare Conferences
2. ViroPharma Provides 2008 Outlook
3. ViroPharma to Present at the BIO CEO & Investor Conference
4. ViroPharma to Release 2007 Fourth Quarter and Full Year Financial Results on February 27, 2008
5. ViroPharma to Present at the Susquehanna Financial Group Second Annual Significant Options in Healthcare Conference
6. ViroPharma to Present at the Cowen & Company 28th Annual Healthcare Conference
7. ViroPharma to Present at the Seventh Annual JMP Securities Research Conference
8. ViroPharma to Present at Two Upcoming Healthcare Conferences
9. Viropharma Comments On Upcoming FDA Advisory Committee Meeting
10. ViroPharma Provides Update on Upcoming FDA Advisory Committee Meeting to Discuss Bioequivalence of Locally Acting Gastrointestinal Drugs
11. Clinical Data Acquires Epidauros Biotechnologie AG, Significantly Enhancing Proprietary Genetic Biomarker Portfolio
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/1/2015)... April 1, 2015  ValGenesis Inc., the market leader ... that it has completed its Service Organization Controls 2 ... (AICPA, Professional Standards) for the period of January 1 ... ... The SOC 2 examination is ...
(Date:4/1/2015)... , Mar. 30, 2015 Research and Markets ... addition of the "Blood Screening Market by ... Chemiluminescence Immunoassay, Next Generation Sequencing, Western Blotting), Product ... - Forecasts to 2019 " report to ... is expected to reach $2.55 billion by 2019 ...
(Date:4/1/2015)... NEW YORK , April 1, 2015 ... biopharmaceutical company advancing protein biologic therapies and oncology ... the Company,s 2014 achievements and a strategic update ... progress the Company has made in the areas ... its MuGard programs, the FDA clearance of the ...
(Date:4/1/2015)... The concept of “spot reducing” areas is a huge ... Fasciology, Ashley Black, says that even the idea of being ... to wait for the whole fat system to reduce is ... cooling procedures, the only well known way to spot ... a highly invasive procedure.” It is common knowledge that weight ...
Breaking Biology Technology:ValGenesis Inc. Successfully Completes Service Organization Controls 2 (SOC 2) Report under AT Section 101 2ValGenesis Inc. Successfully Completes Service Organization Controls 2 (SOC 2) Report under AT Section 101 3Global Blood Screening (Nucleic Acid Amplification Test, ELISA, Rapid Test, Chemiluminescence Immunoassay, Next Generation Sequencing, Western Blotting) Market 2015-2019 2Global Blood Screening (Nucleic Acid Amplification Test, ELISA, Rapid Test, Chemiluminescence Immunoassay, Next Generation Sequencing, Western Blotting) Market 2015-2019 3PlasmaTech Biopharmaceuticals Provides Strategic Update for 2015 and Review of 2014 Acheivements 2PlasmaTech Biopharmaceuticals Provides Strategic Update for 2015 and Review of 2014 Acheivements 3PlasmaTech Biopharmaceuticals Provides Strategic Update for 2015 and Review of 2014 Acheivements 4PlasmaTech Biopharmaceuticals Provides Strategic Update for 2015 and Review of 2014 Acheivements 5PlasmaTech Biopharmaceuticals Provides Strategic Update for 2015 and Review of 2014 Acheivements 6Hybrid Health Guru, Ashley Black, announces that her invention The FasciaBlaster™ rivals the “fat cooling” procedures that reduce exercise and diet resistant fat pockets. 2Hybrid Health Guru, Ashley Black, announces that her invention The FasciaBlaster™ rivals the “fat cooling” procedures that reduce exercise and diet resistant fat pockets. 3
... The medical imaging company SyntheticMR AB, ... order for their magnetic resonance imaging software from Umeå ... be used in clinical practice to monitor the treatment ... SyMRI Diagnostics, includes tools to automatically estimate a measure ...
... Verenium Corporation (Nasdaq: VRNM ), a leading ... of high-performance enzymes, today announced James Levine, President and ... Mr. Levine will present at the upcoming ... September 12, 2011.  The presentation is expected to begin ...
... Switzerland, September 1, 2011 Study Assessing ... in mid 2012 Kuros Biosurgery AG, a ... and bioactive-biomaterial combination products for trauma, wound and spinal ... a Phase IIb clinical trial designed to investigate KUR-211 ...
Cached Biology Technology:Swedish University Hospital Improves Monitoring of Treatment Efficacy in Multiple Sclerosis With Synthetic MRI Innovation 2Swedish University Hospital Improves Monitoring of Treatment Efficacy in Multiple Sclerosis With Synthetic MRI Innovation 3Verenium to Present at Upcoming Conferences 2Verenium to Present at Upcoming Conferences 3Kuros Completes Patient Recruitment in a Phase IIb Clinical Trial With KUR-211 for Diabetic Foot Ulcers 2Kuros Completes Patient Recruitment in a Phase IIb Clinical Trial With KUR-211 for Diabetic Foot Ulcers 3
(Date:3/20/2015)... , Mar. 20, 2015 Research and Markets ... addition of the "India Sensors Market Forecast ... The sensor market is projected to ... Consumer electronics, automotive, industrial and healthcare ... in the country. In addition, adoption of MEMS ...
(Date:3/20/2015)... , March 20, 2015 NXT-ID, Inc. ... biometric authentication company focused on the growing mobile commerce ... wallet is one of the products featured in 2015 ... 20th at 11:00 PM EST on the DIY Network. ... Las Vegas , site of the ...
(Date:3/19/2015)...  NXT-ID, Inc. (NASDAQ: NXTD ) ("NXT-ID" or ... mobile commerce market, announces its biometric payment technology, the Wocket® ... this week on Washington DC,s Fox ... segment "The Next Great Thing", host Laura Evans ... and ,a really big breakthrough in mobile payment.,  ...
Breaking Biology News(10 mins):India Sensors Market Forecast and Opportunities 2020 - STMicroelectronics held the largest share in 2014 2India Sensors Market Forecast and Opportunities 2020 - STMicroelectronics held the largest share in 2014 3NXT-ID's Wocket Biometric Smart Wallet to Air on "I Want That" International CES Special 2NXT-ID's Wocket Biometric Smart Wallet to Air on "I Want That" International CES Special 3NXT-ID's Wocket Smart Wallet Featured on Fox News Segment, "The Next Great Thing" 2NXT-ID's Wocket Smart Wallet Featured on Fox News Segment, "The Next Great Thing" 3
... In 2005, the overall cost of patients' time spent on cancer ... to a new study in the January 3 issue of the ... for the 11 cancers studied and for different phases of cancer ... the direct medical costs of cancer care, but few have attempted ...
... the January issue of the journal Cell Metabolism, published by ... the formation of a poorly understood type of muscle. Moreover, ... IIX fibers were able to run farther and at higher ... ultimately lead to novel drugs designed to change the composition ...
... insect cells ?not in eggs, where flu vaccines currently available ... effective as conventional vaccines in protecting people against the flu, ... the Journal of the American Medical Association. , Removing eggs ... health officials seeking to protect the population from seasonal flu ...
Cached Biology News:Study calculates patient time costs associated with cancer care 2Study calculates patient time costs associated with cancer care 3'Marathon mice' elucidate little-known muscle type 2'Marathon mice' elucidate little-known muscle type 3Bypassing eggs, flu vaccine grown in insect cells shows promise 2Bypassing eggs, flu vaccine grown in insect cells shows promise 3
HybriWell™ hybridization sealing system, 20 mm diameter chamber, 0.15 mm deep *set of 100*...
Recombinant Equine TNF-alpha/TNFSF1A, CF...
GRADIENT MAKER, 30 ML, 1 EA. Category: Protein Vertical Instruments....
DALT GRADIENT MAKER,230V, 1 EA. Category: 2D DALT Systems....
Biology Products: